MedTrace Logo

Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer

NCT04840472 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-12-24

No results posted yet for this study

Summary

The primary purpose of the study is to assess the safety of 111In-panitumumab as a molecular imaging agent in patients with Head and Neck Squamous Cell Carcinoma.

The secondary objective is to compare sensitivity and specificity of identifying sentinel lymph nodes by systemic injection of 111In-panitumumab prior to Day of Surgery versus conventional local injection with an optical dye at the time of surgery.

Conditions

Interventions

DRUG

111I-n panitumumab

Imaging Agent

PROCEDURE

Single photon emission computed tomography/computed tomography (SPECT/CT) scans

Day 1 to 5 (Day of Surgery inclusive)

Sponsors & Collaborators

Principal Investigators

  • Fred Baik, MD · Stanford Universiy

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04840472 on ClinicalTrials.gov